相似文献
1
Updates on systemic therapy for cervical cancer.宫颈癌系统治疗进展。
Indian J Med Res. 2021 Aug;154(2):293-302. doi: 10.4103/ijmr.IJMR_4454_20.
2
Targeted Agents in Cervical Cancer: Beyond Bevacizumab.宫颈癌的靶向药物：不止贝伐珠单抗。
Curr Oncol Rep. 2018 Apr 2;20(5):40. doi: 10.1007/s11912-018-0680-3.
3
Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.免疫治疗和系统治疗在转移性/复发性子宫内膜和宫颈癌中的应用。
Clin Oncol (R Coll Radiol). 2021 Sep;33(9):608-615. doi: 10.1016/j.clon.2021.07.002. Epub 2021 Jul 24.
4
Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.超越化疗：宫颈癌靶向治疗概述与综述
Clin Ther. 2016 Mar;38(3):449-58. doi: 10.1016/j.clinthera.2016.02.007. Epub 2016 Feb 28.
5
Bevacizumab for the treatment of cervical cancer.贝伐单抗用于治疗宫颈癌。
Expert Opin Biol Ther. 2016;16(3):407-19. doi: 10.1517/14712598.2016.1145208.
6
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗或安慰剂联合化疗（伴或不伴贝伐单抗）用于持续性、复发性或转移性宫颈癌的健康相关生活质量（KEYNOTE-826）：一项随机、双盲、安慰剂对照的3期试验。
Lancet Oncol. 2023 Apr;24(4):392-402. doi: 10.1016/S1470-2045(23)00052-9. Epub 2023 Mar 3.
7
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.一线铂类方案治疗后复发/晚期宫颈癌患者的管理：我们目前的状况如何？文献综述
Crit Rev Oncol Hematol. 2016 Dec;108:164-174. doi: 10.1016/j.critrevonc.2016.11.006. Epub 2016 Nov 15.
8
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).贝伐珠单抗和阿替利珠单抗联合紫杉醇与紫杉醇联合贝伐珠单抗用于治疗转移性（IVB 期）、持续性或复发性宫颈癌的铂类化疗的随机 III 期试验：BEATcc 研究（ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030）。
Int J Gynecol Cancer. 2020 Jan;30(1):139-143. doi: 10.1136/ijgc-2019-000880. Epub 2019 Oct 23.
9
STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER.宫颈癌的贝伐珠单抗标准治疗：靶向治疗。
Rev Invest Clin. 2020;72(4):213-218. doi: 10.24875/RIC.20000061.
10
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.针对持续性、复发性或转移性宫颈癌的血管内皮生长因子（VEGF）靶向治疗。
Cochrane Database Syst Rev. 2021 Mar 4;3(3):CD013348. doi: 10.1002/14651858.CD013348.pub2.
引用本文的文献
1
Cervical cancer treatment and nursing considerations: Best practices for effective care.宫颈癌的治疗与护理考量：有效护理的最佳实践
Can Oncol Nurs J. 2025 Jan 1;35(1):244-263. eCollection 2025 Winter.
2
Role of indoleamine 2,3-Dioxygenase 1 in modulating the malignant biological behavior of cervical cancer cells through the Tryptophan-Kynurenine pathway.吲哚胺2,3-双加氧酶1通过色氨酸-犬尿氨酸途径调控宫颈癌细胞恶性生物学行为的作用
J Mol Histol. 2025 Aug 22;56(5):276. doi: 10.1007/s10735-025-10570-9.
3
Development of a Mitochondrial Permeability Transition-Driven Necrosis-Related Prognostic Signature in Cervical Cancer: Integrating Bulk Transcriptomic and Single-Cell Data.基于线粒体通透性转换驱动的坏死相关预后特征在宫颈癌中的研究：整合批量转录组学和单细胞数据
Cancer Med. 2025 Aug;14(15):e71094. doi: 10.1002/cam4.71094.
4
Therapies and nanotherapies for cervical cancer (Review).宫颈癌的治疗与纳米治疗（综述）
Biomed Rep. 2025 Jun 4;23(2):132. doi: 10.3892/br.2025.2010. eCollection 2025 Aug.
5
The Sensitive Genes for Cervical Cancer: Two-Sample Mendelian Randomization with Experimental Validation.宫颈癌的敏感基因：基于实验验证的两样本孟德尔随机化研究
Int J Womens Health. 2025 May 26;17:1511-1532. doi: 10.2147/IJWH.S516444. eCollection 2025.
6
Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report.一线替雷利珠单抗联合贝伐单抗化疗后放疗并维持治疗，使伴有主动脉旁淋巴结转移的高危局部晚期宫颈癌完全缓解：一例报告
Front Immunol. 2025 May 1;16:1573202. doi: 10.3389/fimmu.2025.1573202. eCollection 2025.
7
Cadonilimab plus chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis.卡度尼利单抗联合化疗作为持续性、复发性或转移性宫颈癌的一线治疗：一项成本效益分析
Front Immunol. 2025 Apr 3;16:1562875. doi: 10.3389/fimmu.2025.1562875. eCollection 2025.
8
Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.阿替利珠单抗联合贝伐单抗及化疗与贝伐单抗联合化疗治疗转移性宫颈癌的成本效益分析
Front Pharmacol. 2024 Oct 21;15:1476256. doi: 10.3389/fphar.2024.1476256. eCollection 2024.
9
Artificial Intelligence Algorithms in Predictive Factors for Hematologic Toxicities During Concurrent Chemoradiation for Cervical Cancer.人工智能算法在宫颈癌同步放化疗期间血液学毒性预测因素中的应用
Cureus. 2024 Oct 1;16(10):e70665. doi: 10.7759/cureus.70665. eCollection 2024 Oct.
10
The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study.一线含铂和紫杉醇治疗的晚期和复发性宫颈癌患者的结局：有或无免疫检查点抑制剂适应证的比较研究。
BMC Cancer. 2024 Oct 11;24(1):1267. doi: 10.1186/s12885-024-12989-x.
本文引用的文献
1
Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15-29 Years in the United States, 1999-2017: An Ecologic Study.评估 HPV 疫苗接种对 1999-2017 年间美国 15-29 岁女性宫颈癌发病率的影响：一项生态学研究。
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):30-37. doi: 10.1158/1055-9965.EPI-20-0846. Epub 2020 Oct 20.
2
HPV Vaccination and the Risk of Invasive Cervical Cancer.HPV 疫苗接种与浸润性宫颈癌风险。
N Engl J Med. 2020 Oct 1;383(14):1340-1348. doi: 10.1056/NEJMoa1917338.
3
Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia.治疗人乳头瘤病毒相关宫颈上皮内瘤变的治疗性疫苗研究进展。
J Obstet Gynaecol Res. 2020 Jul;46(7):989-1006. doi: 10.1111/jog.14276. Epub 2020 May 10.
4
Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.基于免疫检查点抑制剂的宫颈癌免疫治疗：未来方向。
Int J Mol Sci. 2020 Mar 27;21(7):2335. doi: 10.3390/ijms21072335.
5
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.HPV 疫苗接种和宫颈筛查对宫颈癌消除的影响：78 个低收入和中低收入国家的比较建模分析。
Lancet. 2020 Feb 22;395(10224):575-590. doi: 10.1016/S0140-6736(20)30068-4. Epub 2020 Jan 30.
6
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.2018 年宫颈癌发病率和死亡率的估计：全球分析。
Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4.
7
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.尼伏鲁单抗单药治疗复发性或转移性宫颈癌、阴道癌或外阴癌的安全性和疗效：来自 I/II 期 CheckMate 358 试验的结果。
J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5.
8
Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.顺铂和吉西他滨新辅助化疗联合放化疗对比单纯放化疗治疗局部晚期宫颈癌的随机 II 期临床试验。
J Clin Oncol. 2019 Nov 20;37(33):3124-3131. doi: 10.1200/JCO.19.00674. Epub 2019 Aug 26.
9
A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.一项比较局部晚期宫颈癌患者同期放化疗与同期放化疗后辅助化疗的随机对照临床试验：ACTLACC 试验。
J Gynecol Oncol. 2019 Jul;30(4):e82. doi: 10.3802/jgo.2019.30.e82. Epub 2019 Apr 10.
10
Turning the corner on therapeutic cancer vaccines.癌症治疗性疫苗迎来转机。
NPJ Vaccines. 2019 Feb 8;4:7. doi: 10.1038/s41541-019-0103-y. eCollection 2019.
Zotero 插件